Showing 4781-4790 of 10571 results for "".
- Suneva to Distribute Sinclair Pharma's Silhouette Instalift Sutureshttps://practicaldermatology.com/news/suneva-to-distribute-sinclair-pharmas-silhouette-instalift-sutures/2460372/Suneva Medical, Inc. is the exclusive North American distributor for Sinclair Pharma's Silhouette Instalift sutures "We are excited to welcome Silhouette Instalift to our already broad regenerative aesthetics portfolio,"
- Bimini Health Tech’s Dermapose Access Office-Based Fat Harvesting System Scores FDA 510(k) clearancehttps://practicaldermatology.com/news/bimini-health-techs-dermapose-access-office-based-fat-harvesting-system-scores-fda-510k-clearance/2460368/Bimini Health Tech’s received US Food and Drug Administration (FDA) 510(k) clearance for its Dermapose Access, a novel fat harvesting system. Designed for office use, the launch of the Dermapose Access sy
- Label Expansion: Amgen's Otezla Adds Scalp Datahttps://practicaldermatology.com/news/label-expansion-amgens-otezla-adds-scalp-data/2460359/With FDA approval of a supplemental New Drug Application (sNDA), the label for Amgen's Otezla will now be updated to include scalp psoriasis data from the Phase 3 STYLE trial. The label expansion makes Otezla the only oral treatment option to have data specific to moderate
- Can JAK Inhibition Put the Brakes on COVID-19-Associated Cytokine Storm? Incyte Hopes Sohttps://practicaldermatology.com/news/can-jak-inhibition-put-the-brakes-on-covid-19-associated-cytokine-storm-incyte-hopes-so/2460355/Incyte’s JAK inhibitor may play a role in stopping COVID-19-associated cytokine storms. Incyte is starting RUXCOVID, a global, randomized, double-blind, placebo-controlled Phase 3 clinical trial evaluating the efficacy and safety of ruxolit
- Rosacea Awareness Month Brings Focus to Common Skin Diseasehttps://practicaldermatology.com/news/rosacea-awareness-month-brings-focus-to-common-skin-disease/2460342/It’s Rosacea Awareness Month, and the National Rosacea Society (NRS) continues to educate the public on this potentially serious condition estimated to affect more than 16 million Americans. “Although the occurrence of rosacea has been well documented over the centuries, vir
- Antimalarials for COVID-19: Will Demand Outweigh Supply?https://practicaldermatology.com/news/antimalarials-for-covid-19-will-demand-outweigh-supply/2460337/Chloroquine and hydroxychloroquine may help treat COVID-19, but if mass prophylaxis is advised it's possible that demand will outweigh the supply of antimalarials, say Italian doctors in a letter published online today in the Annals of the Rheumatic Diseases. The results of prelimin
- Wontech Scores FDA Nod for Sandro Dual Laserhttps://practicaldermatology.com/news/wontech-scores-fda-nod-for-sandro-dual-laser/2460333/The U.S. Food and Drug Administration granted 510 (K) marketing clearance to Wontech’s Sandro Dual, a hybrid Nd:YAG & Alexandrite laser device. In the hybrid mode, by irradiating a short time difference between two wavelengths of 755nm and 1064nm, the laser accurately hits its
- Isdin Taps Professional Golfer Jessica Korda As New Sports Ambassadorhttps://practicaldermatology.com/news/isdin-taps-professional-golfer-jessica-korda-as-new-sports-ambassador-1/2460330/Professional golfer and LPGA star Jessica Korda is ISDIN’s new sports ambassador. As part of the campaign, Korda is sharing how she keeps her skin looking its best on and off the golf course with ISDIN products. "ISDIN formulates unique and innovative products with
- BiomX’s BX001 for Acne-Prone Skin Performs Well in Phase 1 Trialhttps://practicaldermatology.com/news/biomxs-bx001-for-acne-prone-skin-performs-well-in-phase-1-1/2460328/BiomX Inc.’s lead candidate BX001 for acne-prone skin met its primary endpoint of safety and tolerability for both doses of BX001 as well as a statistically significant reduction of Cutibacterium acnes (C. acnes) levels for the high dos
- FDA Grants Breakthrough Status for Baricitinib in AAhttps://practicaldermatology.com/news/fda-grants-breakthrough-status-for-baricitinib-in-alopecia-1/2460308/The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Eli Lilly and Company and Incyte Corporation’s baricitinib for the treatment of alopecia areata (AA). Baricitinib is currently approved for the treatment of adults with moderately to severe